We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Proposed Treatment Aims to Re-Sensitize Cancer Cells

By LabMedica International staff writers
Posted on 08 Nov 2018
Print article
Image: Pancreatic cancer cells deficient in the expression of the human gene known as Schlafen 11 and resistant to chemotherapy (left panels) were re-sensitized to chemotherapeutic treatment (middle and right panels) by inhibiting the expression of the transfer RNA known as tRNA-Leu-TAA through specially designed antisense oligonucleotides (Photo courtesy of Manqing Li, Michael David Laboratory, University of California, San Diego).
Image: Pancreatic cancer cells deficient in the expression of the human gene known as Schlafen 11 and resistant to chemotherapy (left panels) were re-sensitized to chemotherapeutic treatment (middle and right panels) by inhibiting the expression of the transfer RNA known as tRNA-Leu-TAA through specially designed antisense oligonucleotides (Photo courtesy of Manqing Li, Michael David Laboratory, University of California, San Diego).
Cancer cells that lack the Schlafen 11 gene frequently develop resistance to commonly used DNA-damaging (DDA) chemotherapeutic drugs, but recent research suggests that this resistance may be reversible.

The Schlafen 11 (SLFN11) gene encodes a protein inhibitor of DNA replication that promotes cell death in response to DNA damage. It is the dominant determinant of sensitivity to DNA-damaging anticancer drugs and acts by mediating cell death in response to DNA damage. Earlier studies on SLFN11 in mice showed that the protein interfered with the replication of HIV in infected human cells by blocking the synthesis of viral proteins without suppressing the host cell's overall ability to synthesize proteins.

Investigators at the University of California, San Diego (USA) examined the link between SLFN11 expression and cancer cell DDA resistance.

They reported in the October 29, 2018, online edition of the journal Nature Structural and Molecular Biology that upon DDA treatment SLFN11 preferentially inhibited translation of the serine/threonine kinases ATR (ataxia telangiectasia and Rad3-related protein) and ATM (ATM serine/threonine kinase). ATM and ATR are known for their central roles in DNA damage repair. Therefore, cells lacking SLFN11 activity would retain ATR and ATM activity, be able to repair DNA damage, and be resistant to DDA treatment.

The investigators found that activated Schlafen 11 protein cleaved a specific subset of transfer RNAs (tRNA-Leu-TAA), which feature an extra stem loop in their structures. Among the tRNAs affected are all those for the amino acids leucine and serine. When tRNA-Leu-TAA is destroyed by cleavage, ATM and ATR become the most susceptible targets of protein synthesis inhibition by Schlafen 11.

Deliberate reduction of tRNA-Leu-TAA levels was shown to be sufficient to abolish ATR protein expression and restore the DDA sensitivity of SLFN11-deficient cells. This finding supported the notion that SLFN11-deficient tumor cells could be re-sensitized to DDAs by targeting ATR or tRNA-Leu-TAA.

"We found that if you expose cells that have Schlafen 11 to DNA damaging agents, the Schlafen 11 protein gets activated and suppresses the synthesis of ATM and ATR—that is essentially what kills the tumor cells," said senior author Dr. Michael David, professor of molecular biology at the University of California, San Diego. "In cells that do not express Schlafen 11, you do not get this downregulation of ATM/ATR and that essentially allows the tumor cells to survive. These results carry potential applications in immunology and virology since the fundamental mechanisms behind Schlafen 11 are also at play in anti-HIV processes and likely with other viruses."

Related Links:
University of California, San Diego

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Mumps Virus Test
ZEUS ELISA Mumps IgG Test System
New
Aspergillus Test
REALQUALITY Aspergillus

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.